Celgene Corp. (CELG)

CELG (NASDAQ:Biotechnology) EQUITY
$95.61
pos +0.00
+0.00%
Today's Range: 93.94 - 95.66 | CELG Avg Daily Volume: 6,716,600
Last Update: 02/23/18 - 4:00 PM EST
Volume: 0
YTD Performance: -10.14%
Open: $0.00
Previous Close: $93.78
52 Week Range: $88.32 - $147.17
Oustanding Shares: 752,176,000
Market Cap: 70,621,804,688
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 16 15 18 17
Moderate Buy 0 0 0 0
Hold 12 13 11 10
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.86 1.93 1.76 1.74
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 25.76
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
25.76 25.79 22.60
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-10.82% -19.84% -24.02%
GROWTH 12 Mo 3 Yr CAGR
Revenue 17.40 0.70 0.19
Net Income 46.69 0.50 0.14
EPS 46.19 0.50 0.15
Earnings for CELG:
EBITDA 3.65B
Revenue 12.82B
Average Earnings Estimates
Qtr (03/18) Qtr (06/18) FY (12/18) FY (12/19)
Average Estimate $1.78 $1.88 $7.68 $9.24
Number of Analysts 5 2 2 2
High Estimate $1.90 $1.89 $7.70 $9.30
Low Estimate $1.71 $1.86 $7.66 $9.17
Prior Year $1.53 $1.68 $6.84 $7.68
Growth Rate (Year over Year) 16.21% 11.61% 12.28% 20.25%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
I continue to deploy some of the 'dry powder' into the market after its recent hiccup.
Bullish
Feb 13, 2018 | 8:11 AM EST
Celgene was upgraded to "overweight" at Barclays with a $105 price target.
In this tape, weakness may just be a sign of rest and better times to come.
The biotech sector has seen a big rally, but there are still opportunities.
Consumer spending should be more than solid given wage increases.
All three indices closed the day in record territory.

M&A Rumors Rise Again Real Money Pro($)

About a half hour to go before the markets open for the last trading day of the week. Acorda Therapeutics (ACOR) is up more than 10% in pre-market trading on rumors it could be the target of several potential suitors, including Biogen (BIIB) .

Columnist Conversations

Buffett says he has $116 billion in cash to spend on deals, but is having problems finding an attractive purch...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.